An experimental Eli Lilly and Co. lung cancer drug, which some investors had given up on due to past setbacks, extended patient survival in a late-stage study, reviving hopes for the medicine and sending company shares 4% higher.
Lilly lung cancer drug boosts survival, shares jump
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You
Sponsored Content